Point72 chief Cohen loses bid to dismiss lawsuits by investors

Elan and Wyeth shareholders claim former SAC Capital lost money over insider trading

A US federal judge has rejected billionaire investor Steven A Cohen's bid to dismiss lawsuits by shareholders of pharma firms Elan and Wyeth who claimed they lost money because his firm SAC Capital Advisors LP conducted insider trading in the drugmakers' stocks.

In a decision made public yesterday, US District Judge Victor Marrero in Manhattan allowed the entire case against Mr Cohen and SAC to go forward, apart from claims that investors agreed should be dismissed because they were brought too late.

He also rejected dismissal requests by defendants Mathew Martoma, a former portfolio manager at SAC's CR Intrinsic unit found guilty in February of insider trading, and Sidney Gilman, a University of Michigan medical professor.

SAC is now called Point72 Asset Management, and invests Mr Cohen's fortune from its Stamford, Connecticut offices. A spokesman, Jonathan Gasthalter, declined to comment. Ethan Wohl, a lawyer for the investors, declined to comment.


Confidential tips

The lawsuit stemmed from US charges that Martoma generated $275 million of illegal gains for SAC by trading on prof Gilman’s confidential tips about an Alzheimer’s drug trial before results were released on July 29th, 2008.

The two pharma firms were working in a joint venture on the trails of bapineuzumab.

Investors claimed to suffer damages by trading in Elan and Wyeth stock and options at the same time as SAC, but without the benefit of inside information. Elan is now part of Perrigo and Wyeth is now part of Pfizer.

SAC was also implicated in other insider trading, eventually pleading guilty to fraud and paying $1.8 billion in settlements with US authorities. Mr Cohen has not been criminally charged.

In seeking to dismiss the investor lawsuit, SAC said "contemporaneous traders are not harmed by insider trading" and that it had already given up illegal gains in its $602 million settlement with the US Securities and Exchange Commission.

But Judge Marrero, who delayed approving that pact because it did not require SAC to admit or deny wrongdoing, said the settlement did not establish to a “scientific truth” what SAC should owe.

He also said it was too soon to dismiss damages claims over a plunge in Elan’s stock price, two days after the Alzheimer’s drug trial results were released, over problems with its multiple sclerosis drug Tysabri.

Avoid losses

Even if SAC did not know about the problems, Judge Marrero said it was unclear whether the investors had sufficient time after the results were released to avoid more losses by selling shares.

A lawyer for Martoma could not immediately be reached for comment. Marc Mukasey, a lawyer for Prof Gilman, said: "We will continue to press forward and defend the civil suit."

Martoma faces a September 8th sentencing. Prof Gilman was not criminally charged. – ( Reuters)